Clene’s cash, cash equivalents and marketable securities totaled $42.1 million as of September 30, 2023, compared to $23.3 million as of December 31, 2022. Clene expects that its resources as of September 30, 2023, will be sufficient to fund its operations into the third quarter of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLNN:
- Clene Reports Third Quarter 2023 Financial Results and Operating Highlights
- Clene awarded $45.1M four-year grant from NINDS for CNM-Au8
- National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS
- Clene announces publication on CNM-Au8 catalytic mechanism of action
- Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference
